Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

[1]  M. Weinblatt,et al.  Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis , 2019, Arthritis & rheumatology.

[2]  Daniel B. Shin,et al.  Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study , 2018, European heart journal.

[3]  M. Genovese,et al.  Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment , 2018, The Journal of Rheumatology.

[4]  J. Salmon,et al.  Antiphospholipid Antibodies Inhibit Trophoblast Toll‐Like Receptor and Inflammasome Negative Regulators , 2018, Arthritis & rheumatology.

[5]  Yoshiya Tanaka,et al.  Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy , 2017, Arthritis & rheumatology.

[6]  D. M. van der Heijde,et al.  Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment , 2017, Arthritis & rheumatology.

[7]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[8]  Stanley B. Cohen,et al.  Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials , 2017, Annals of the rheumatic diseases.

[9]  M. Abrahamowicz,et al.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap , 2016, Annals of the rheumatic diseases.

[10]  M. Dougados,et al.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study , 2016, Annals of the rheumatic diseases.

[11]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[12]  Yoshiya Tanaka,et al.  Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis , 2016, Expert review of clinical immunology.

[13]  Shun-Chiao Chang,et al.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow‐Up: Results From the Nurses’ Health Study , 2016, Arthritis care & research.

[14]  S. Bernatsky,et al.  Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments , 2016, Arthritis & rheumatology.

[15]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[16]  Yoshiya Tanaka,et al.  Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study , 2016, The Journal of Rheumatology.

[17]  W. Williams,et al.  AB0492 Evaluation of Potential Drug-Drug Interactions with Baricitinib , 2015 .

[18]  M. Genovese,et al.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate , 2014, Annals of the rheumatic diseases.

[19]  E. Lee,et al.  Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies , 2014, The Journal of Rheumatology.

[20]  S. Schneeweiss,et al.  Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis , 2013, Arthritis care & research.

[21]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[22]  G. Burmester,et al.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease , 2012, Annals of the rheumatic diseases.

[23]  J. Kremer,et al.  Integrated safety in tocilizumab clinical trials , 2011, Arthritis research & therapy.

[24]  M. Dougados,et al.  Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. , 2011, Clinical and experimental rheumatology.

[25]  A. Gottlieb,et al.  Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. , 2011, Journal of drugs in dermatology : JDD.

[26]  J. Fridman,et al.  Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.

[27]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[28]  K. Rothman.  A potential bias in safety evaluation during open‐label extensions of randomized clinical trials , 2004, Pharmacoepidemiology and drug safety.

[29]  N. Baber,et al.  International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). , 1994, British journal of clinical pharmacology.